New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
04
06
2020
revised:
25
09
2020
accepted:
26
01
2021
pubmed:
6
2
2021
medline:
19
1
2022
entrez:
5
2
2021
Statut:
ppublish
Résumé
Prosurvival and antiapoptotic B cell lymphoma-2 (Bcl-2) family proteins are often overexpressed in cutaneous melanoma, one of the most aggressive types of human cancer. They are also implicated in resistance to therapy and participate in melanoma progression by regulating various processes, including cell proliferation, migration, invasion, and crosstalk with the tumor microenvironment. In this review, we summarize recent findings related to prosurvival members of the Bcl-2 family beyond their canonical functions in the apoptotic pathway, mainly focusing on their potential roles as diagnostic and prognostic biomarkers in cutaneous melanoma. We also provide an overview of different approaches used to inhibit Bcl-2 proteins in preclinical and clinical studies, which are mainly based on the inhibition of protein expression or the disruption of their antiapoptotic functions.
Identifiants
pubmed: 33545382
pii: S1359-6446(21)00059-3
doi: 10.1016/j.drudis.2021.01.027
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1126-1135Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.